Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries – Leukemia

Large European retrospective analysis of 3700 patients >=70 with leukemia showed median OS of 10.9 months with high intensity treatment vs 9.2 months with HMA. Early mortality was significantly higher (6.8%, n=116) in the high intensity treated patients. Survival significantly splits at 3 and 5 years.

Read the full article here

Related Articles